Literature DB >> 25367836

Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study.

Rohini G Madane1, Hitendra S Mahajan1.   

Abstract

Cancer nanotherapeutics is beginning to overwhelm the global research and viewed to be the revolutionary treatment regime in the medical field. This investigation describes the development of a stable nanostructured lipid carrier (NLC) system as a carrier for curcumin (CRM). The CRM-loaded NLC developed as a particle with the size of 146.8 nm, a polydispersity index of 0.18, an entrapment efficiency (EE) of 90.86%, and the zeta potential (ZP) of -21.4 mV. Besides, the increased cytotoxicity of CRM-NLC than that of CRM to astrocytoma-glioblastoma cell line (U373MG) in the cancer cell lines was observed. Results of biodistribution studies showed higher drug concentration in brain after intranasal administration of NLCs than PDS. The results of the study also suggest that CRM-NLC is a promising drug delivery system for brain cancer therapy.

Entities:  

Keywords:  Curcumin; nanostructured lipid carrier; nasal drug delivery

Mesh:

Substances:

Year:  2014        PMID: 25367836     DOI: 10.3109/10717544.2014.975382

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  28 in total

1.  Curcumin-loaded Nanostructured Lipid Carriers for Ocular Drug Delivery: Design Optimization and Characterization.

Authors:  Prit Lakhani; Akash Patil; Pranjal Taskar; Eman Ashour; Soumyajit Majumdar
Journal:  J Drug Deliv Sci Technol       Date:  2018-07-17       Impact factor: 3.981

2.  Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.

Authors:  Chengsong Cao; Qun Wang; Yong Liu
Journal:  Drug Des Devel Ther       Date:  2019-04-05       Impact factor: 4.162

Review 3.  Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.

Authors:  Wiam El Kheir; Bernard Marcos; Nick Virgilio; Benoit Paquette; Nathalie Faucheux; Marc-Antoine Lauzon
Journal:  Pharmaceutics       Date:  2022-06-01       Impact factor: 6.525

Review 4.  Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.

Authors:  Sara Cunha; Ben Forbes; José Manuel Sousa Lobo; Ana Catarina Silva
Journal:  Int J Nanomedicine       Date:  2021-06-29

Review 5.  Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases.

Authors:  Christos Tapeinos; Matteo Battaglini; Gianni Ciofani
Journal:  J Control Release       Date:  2017-08-26       Impact factor: 9.776

6.  Preparation and Characterization of PEG-albumin-curcumin Nanoparticles Intended to Treat Breast Cancer.

Authors:  R Thadakapally; Arshiya Aafreen; J Aukunuru; M Habibuddin; S Jogala
Journal:  Indian J Pharm Sci       Date:  2016 Jan-Feb       Impact factor: 0.975

Review 7.  Therapeutic Potential of Curcumin for the Treatment of Brain Tumors.

Authors:  Neil V Klinger; Sandeep Mittal
Journal:  Oxid Med Cell Longev       Date:  2016-10-11       Impact factor: 6.543

Review 8.  Improving In Vivo Efficacy of Bioactive Molecules: An Overview of Potentially Antitumor Phytochemicals and Currently Available Lipid-Based Delivery Systems.

Authors:  Lamia Mouhid; Marta Corzo-Martínez; Carlos Torres; Luis Vázquez; Guillermo Reglero; Tiziana Fornari; Ana Ramírez de Molina
Journal:  J Oncol       Date:  2017-05-07       Impact factor: 4.375

9.  Catan-ionic hybrid lipidic nano-carriers for enhanced bioavailability and anti-tumor efficacy of chemodrugs.

Authors:  Bilin Liu; Dan He; Jianyong Wu; Quan Sun; Mi Zhang; Qunyou Tan; Yao Li; Jingqing Zhang
Journal:  Oncotarget       Date:  2017-05-09

10.  In-vitro and in-vivo evaluation of chitosan-based thermosensitive gel containing lorazepam NLCs for the treatment of status epilepticus.

Authors:  Somayeh Taymouri; Mohsen Minaiyan; Farnaz Ebrahimi; Naser Tavakoli
Journal:  IET Nanobiotechnol       Date:  2020-04       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.